154 related articles for article (PubMed ID: 32903249)
1. COVID-19 and Hypercoagulability.
Sholzberg M
Clin Adv Hematol Oncol; 2020 Jul; 18(7):386-389. PubMed ID: 32903249
[No Abstract] [Full Text] [Related]
2. Thromboembolic events and Covid-19.
Ribes A; Vardon-Bounes F; Mémier V; Poette M; Au-Duong J; Garcia C; Minville V; Sié P; Bura-Rivière A; Voisin S; Payrastre B
Adv Biol Regul; 2020 Aug; 77():100735. PubMed ID: 32773098
[TBL] [Abstract][Full Text] [Related]
3. Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?
Tal S; Spectre G; Kornowski R; Perl L
Acta Haematol; 2020; 143(5):417-424. PubMed ID: 32396903
[TBL] [Abstract][Full Text] [Related]
4. Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
Laurence J; Mulvey JJ; Seshadri M; Racanelli A; Harp J; Schenck EJ; Zappetti D; Horn EM; Magro CM
Clin Immunol; 2020 Oct; 219():108555. PubMed ID: 32771488
[TBL] [Abstract][Full Text] [Related]
5. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
[TBL] [Abstract][Full Text] [Related]
6. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Magro G
Virus Res; 2020 Sep; 286():198070. PubMed ID: 32569708
[TBL] [Abstract][Full Text] [Related]
7. After 62 years of regulating immunity, dexamethasone meets COVID-19.
Cain DW; Cidlowski JA
Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.
Mojtabavi H; Saghazadeh A; Rezaei N
Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891
[TBL] [Abstract][Full Text] [Related]
9. Thrombo-inflammatory features predicting mortality in patients with COVID-19: The FAD-85 score.
Wang J; Zhang H; Qiao R; Ge Q; Zhang S; Zhao Z; Tian C; Ma Q; Shen N
J Int Med Res; 2020 Sep; 48(9):300060520955037. PubMed ID: 32960106
[TBL] [Abstract][Full Text] [Related]
10. 2020 - Year of COVID-19.
Lillicrap D; Morrissey JH
J Thromb Haemost; 2020 Sep; 18(9):2081. PubMed ID: 32881334
[No Abstract] [Full Text] [Related]
11. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
12. Coagulopathy and Plausible Benefits of Anticoagulation Among COVID-19 Patients.
Ahmed SI; Khan S
Curr Probl Cardiol; 2020 Sep; 45(9):100648. PubMed ID: 32703535
[TBL] [Abstract][Full Text] [Related]
13. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications.
Merrill JT; Erkan D; Winakur J; James JA
Nat Rev Rheumatol; 2020 Oct; 16(10):581-589. PubMed ID: 32733003
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.
Tang N; Bai H; Chen X; Gong J; Li D; Sun Z
J Thromb Haemost; 2020 May; 18(5):1094-1099. PubMed ID: 32220112
[TBL] [Abstract][Full Text] [Related]
15. ISTH DIC subcommittee communication on anticoagulation in COVID-19.
Thachil J; Juffermans NP; Ranucci M; Connors JM; Warkentin TE; Ortel TL; Levi M; Iba T; Levy JH
J Thromb Haemost; 2020 Sep; 18(9):2138-2144. PubMed ID: 32881336
[TBL] [Abstract][Full Text] [Related]
16. New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm.
Kanthi Y; Knight JS; Zuo Y; Pinsky DJ
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32530438
[TBL] [Abstract][Full Text] [Related]
17. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Luo W; Li YX; Jiang LJ; Chen Q; Wang T; Ye DW
Trends Pharmacol Sci; 2020 Aug; 41(8):531-543. PubMed ID: 32580895
[TBL] [Abstract][Full Text] [Related]
18. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.
Tang N; Li D; Wang X; Sun Z
J Thromb Haemost; 2020 Apr; 18(4):844-847. PubMed ID: 32073213
[TBL] [Abstract][Full Text] [Related]
19. IL-6: Relevance for immunopathology of SARS-CoV-2.
Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2: An immunogenetics call to arms.
Clark B; Poulton K
Int J Immunogenet; 2020 Aug; 47(4):319-323. PubMed ID: 32654378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
